Cerebral grey matter density is associated with neuroreceptor and neurotransporter availability: A combined PET and MRI study

Positron emission tomography (PET) can be used for in vivo measurement of specific neuroreceptors and transporters using radioligands, while voxel-based morphometric analysis of magnetic resonance images allows automated estimation of local grey matter densities. However, it is not known how regional neuroreceptor or transporter densities are reflected in grey matter densities. Here, we analyzed brain scans retrospectively from 328 subjects and compared grey matter density estimates with three different neuroreceptors and transporter availabilities. µ-opioid receptors (MORs) were measured with [11C]carfentanil (162 scans), dopamine D2 receptors with [11C]raclopride (92 scans) and serotonin transporters (SERT) with [11C]MADAM (74 scans). The PET data were modelled with simplified reference tissue model. Voxel-wise correlations between binding potential and grey matter density images were computed. Regional binding of all the used radiotracers was associated with grey matter density in region and ligand-specific manner independently of subjects' age or sex. These data show that grey matter density and MOR and D2R neuroreceptor / SERT availability are correlated, with effect sizes (r2) ranging from 0.04 to 0.69. This suggests that future studies comparing PET outcome measure different groups (such as patients and controls) should also analyze interactive effects of grey matter density and PET outcome measures.

[1]  Uygar Tuna,et al.  Image quantification in high-resolution PET assessed with a new anthropomorphic brain phantom , 2013, 2013 IEEE Nuclear Science Symposium and Medical Imaging Conference (2013 NSS/MIC).

[2]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[3]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[4]  S. Kasper,et al.  The serotonin transporter in psychiatric disorders: insights from PET imaging. , 2015, The lancet. Psychiatry.

[5]  Denis Guilloteau,et al.  Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[6]  S. Resnick,et al.  Longitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain , 2003, The Journal of Neuroscience.

[7]  Mikko Sams,et al.  Social touch modulates endogenous μ-opioid system activity in humans , 2016, NeuroImage.

[8]  J. Zubieta,et al.  Gender and age influences on human brain mu-opioid receptor binding measured by PET. , 1999, The American journal of psychiatry.

[9]  Robert A Koeppe,et al.  Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. , 2006, Archives of general psychiatry.

[10]  Rui Li,et al.  Cerebral morphology and dopamine D2/D3 receptor distribution in humans: A combined [18F]fallypride and voxel-based morphometry study , 2009, NeuroImage.

[11]  Aki Vehtari,et al.  Interindividual variability and lateralization of μ-opioid receptors in the human brain , 2020, NeuroImage.

[12]  Christer Halldin,et al.  Quantification of serotonin transporter availability with [11C]MADAM — A comparison between the ECAT HRRT and HR systems , 2010, NeuroImage.

[13]  Annalena Venneri,et al.  Review: Parkinson's disease: from synaptic loss to connectome dysfunction , 2016, Neuropathology and applied neurobiology.

[14]  E. Luders,et al.  Voxel-Based Morphometry , 2015 .

[15]  Pia Baldinger,et al.  Serotonin-1A receptor binding is positively associated with gray matter volume — A multimodal neuroimaging study combining PET and structural MRI , 2012, NeuroImage.

[16]  Anatol C. Kreitzer,et al.  Plasticity in gray and white: neuroimaging changes in brain structure during learning , 2012, Nature Neuroscience.

[17]  Lauri Tuominen,et al.  Obesity Is Associated with Decreased μ-Opioid But Unaltered Dopamine D2 Receptor Availability in the Brain , 2015, Journal of Neuroscience.

[18]  R W Baloh,et al.  Brain Volume Changes on Longitudinal Magnetic Resonance Imaging in Normal Older People , 2001, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[19]  L. Nummenmaa,et al.  Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety , 2020, Neuropsychopharmacology.

[20]  Mikko Sams,et al.  Adult attachment style is associated with cerebral μ‐opioid receptor availability in humans , 2015, Human brain mapping.

[21]  W. Heiss,et al.  The sensitivity of 18‐fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease , 2004, European journal of neurology.

[22]  T. Noponen,et al.  Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease , 2017, Neurology.

[23]  Rupert Lanzenberger,et al.  Meta-analysis of molecular imaging of serotonin transporters in major depression , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  Jean Logan,et al.  Brain dopamine and obesity , 2001, The Lancet.

[25]  Aki Vehtari,et al.  Interindividual variability and lateralization of µ-opioid receptors in the human brain , 2019, bioRxiv.

[26]  Penelope A. Lewis,et al.  Ventromedial prefrontal volume predicts understanding of others and social network size , 2011, NeuroImage.

[27]  Mitul A. Mehta,et al.  The dopaminergic basis of human behaviors: A review of molecular imaging studies , 2009, Neuroscience & Biobehavioral Reviews.

[28]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[29]  L. Nummenmaa,et al.  Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity , 2016, Molecular Psychiatry.

[30]  Benson Df,et al.  Posterior cortical atrophy. , 1988, Archives of neurology.

[31]  R. Terry.  Cell death or synaptic loss in Alzheimer disease. , 2000, Journal of neuropathology and experimental neurology.

[32]  Marco Bucci,et al.  Magia: Robust Automated Image Processing and Kinetic Modeling Toolbox for PET Neuroinformatics , 2020, Frontiers in Neuroinformatics.

[33]  D J Brooks,et al.  Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.

[34]  Jonathan E. Peelle,et al.  Adjusting for global effects in voxel-based morphometry: Gray matter decline in normal aging , 2012, NeuroImage.

[35]  Robin I. M. Dunbar,et al.  Social Laughter Triggers Endogenous Opioid Release in Humans , 2017, The Journal of Neuroscience.

[36]  P. Fox,et al.  Identification of a common neurobiological substrate for mental illness. , 2015, JAMA psychiatry.

[37]  N. Volkow,et al.  Imaging dopamine's role in drug abuse and addiction , 2009, Neuropharmacology.

[38]  Floris H. P. van Velden,et al.  Comparison of HRRT and HR+ Scanners for Quantitative (R)-[11C]verapamil, [11C]raclopride and [11C]flumazenil Brain Studies , 2015, Molecular Imaging and Biology.

[39]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[40]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT , 2000, Neurobiology of Aging.

[41]  Faith M. Gunning-Dixon,et al.  Aging of cerebral white matter: a review of MRI findings , 2009, International journal of geriatric psychiatry.

[42]  K. Leenders,et al.  Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. , 1993, Archives of neurology.

[43]  D. Morgan.  The dopamine and serotonin systems during aging in human and rodent brain. A brief review , 1987, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  Dean F. Wong,et al.  Imaging Opiate Receptors in the Human Brain by Positron Tomography , 1985, Journal of computer assisted tomography.

[45]  Lars Farde,et al.  Quantification of serotonin transporter availability with [11C]MADAM — A comparison between the ECAT HRRT and HR systems , 2010, NeuroImage.

[46]  U Ruotsalainen,et al.  Decrease in Human Striatal Dopamine D2 Receptor Density with Age: A PET Study with [11C]Raclopride , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  K. Herholz,et al.  Brain receptor imaging. , 2010, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  Riitta Parkkola,et al.  Obesity is associated with white matter atrophy: A combined diffusion tensor imaging and voxel‐based morphometric study , 2013, Obesity.

[49]  Riitta Parkkola,et al.  Bariatric Surgery Induces White and Grey Matter Density Recovery in the Morbidly Obese: A Voxel‐Based Morphometric Study , 2016, Human brain mapping.

[50]  Lauri Tuominen,et al.  Magia: Robust Automated Image Processing and Kinetic Modeling Toolbox for PET Neuroinformatics , 2018, bioRxiv.

[51]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. , 2000, Neurobiology of aging.

[52]  Ó. Gonçalves,et al.  Posterior cortical atrophy and Alzheimer’s disease: a meta-analytic review of neuropsychological and brain morphometry studies , 2013, Brain Imaging and Behavior.